Open AccessAndrogen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Author(s) -
Emmanuel S. Antonarakis,
Changxue Lu,
Brandon Luber,
Hao Wang,
Yan Chen,
Mari Nakazawa,
Rosa Nadal,
Channing J. Paller,
Samuel R. Denmeade,
Michael A. Carducci,
Mario A. Eisenberger,
Jun Luo
Publication year - 2015
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2015.1341
Subject(s) - enzalutamide , taxane , medicine , cabazitaxel , prostate cancer , oncology , docetaxel , androgen receptor , context (archaeology) , chemotherapy , androgen deprivation therapy , cancer , breast cancer , biology , paleontology
We previously showed that detection of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer (CRPC) was associated with primary resistance to enzalutamide and abiraterone therapy, but the relevance of AR-V7 status in the context of chemotherapy is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom